Research work · 2017
Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal
Floor J.E. Lubberman, Nielka P. van Erp, Rob ter Heine, Carla M.L. van Herpen
Acta Oncologica
Abstract
Since the year 2000, several tyrosine kinase inhibitors (TKIs) have been introduced in the clinical setting to treat metastatic cancers. The TKIs sunitinib, pazopanib, axitinib and very recently, c...